Arizona 2023 Regular Session

Arizona House Bill HB2486 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	REFERENCE TITLE: clinical research; psilocybin; grants; appropriation State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023 HB 2486 Introduced by Representatives Payne: Longdon, Travers, Senator Shope An Act amending title 36, chapter 2, Arizona Revised Statutes, by adding article 5; repealing title 36, chapter 2, article 5, Arizona Revised Statutes; appropriating monies; relating to research grants. (TEXT OF BILL BEGINS ON NEXT PAGE)
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9	REFERENCE TITLE: clinical research; psilocybin; grants; appropriation
10	10	State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023
11	11	HB 2486
12	12	Introduced by Representatives Payne: Longdon, Travers, Senator Shope
13	13
14	14	REFERENCE TITLE: clinical research; psilocybin; grants; appropriation
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24	State of Arizona
25	25
26	26	House of Representatives
27	27
28	28	Fifty-sixth Legislature
29	29
30	30	First Regular Session
31	31
32	32	2023
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40	HB 2486
41	41
42	42
43	43
44	44	Introduced by
45	45
46	46	Representatives Payne: Longdon, Travers, Senator Shope
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64	An Act
65	65
66	66
67	67
68	68	amending title 36, chapter 2, Arizona Revised Statutes, by adding article 5; repealing title 36, chapter 2, article 5, Arizona Revised Statutes; appropriating monies; relating to research grants.
69	69
70	70
71	71
72	72
73	73
74	74	(TEXT OF BILL BEGINS ON NEXT PAGE)
75	75
76	76
77	77
78	78	Be it enacted by the Legislature of the State of Arizona: Section 1. Title 36, chapter 2, Arizona Revised Statutes, is amended by adding article 5, to read: ARTICLE 5. PSILOCYBIN RESEARCH START_STATUTE36-281. Definitions In this article, unless the context otherwise requires: 1. "Advisory council" means the psilocybin research advisory council established by section 36-283. 2. "Department" means the department of HEALTH services. 3. "Director" means the director of the department of health services. END_STATUTE START_STATUTE36-282. Research grants; psilocybin research; priority; immunity A. The director shall provide from monies appropriated competitive research grants for whole mushroom psilocybin phase one, phase two and phase three clinical trials that are capable of being approved by the United States food and drug administration to evaluate the effects of whole mushroom psilocybin on treating any of the following: 1. Post-traumatic stress disorder. 2. Symptoms associated with long COVID-19. 3. Depression. 4. Anxiety disorders. 5. Symptoms associated with end-of-life distress. 6. Obsessive compulsive disorder. 7. substance abuse and addiction disorders. 8. Eating disorders. 9. Chronic pain. 10. Inflammatory disorders. 11. Autoimmune disorders. 12. Seizure disorders. 13. Other degenerative disorders. B. The department shall announce the opening of the application process at least thirty days before applications are available and allow at least ninety days for applicants to complete their submission. The research grants shall be awarded not later than July 1 of each year for three years. If in any year there is not a proposal that meets the criteria for a research grant to be awarded for a whole mushroom psilocybin clinical trial, the director shall postpone the award to the following year. C. Clinical trials that are funded pursuant this section shall prioritize: 1. Using whole mushroom psilocybin cultivated under a schedule I license issued by the United States drug enforcement administration. 2. Using veterans, first responders, frontline health care workers and persons from underserved communities as the research subjects. D. Notwithstanding title 13, chapter 34, a person who receives a grant for a whole mushroom psilocybin clinical trial pursuant to this section and any of the person's employees working on the clinical trial may not be charged with or prosecuted for possession of psilocybin when the person is working on the clinical trial.END_STATUTE START_STATUTE36-283. Psilocybin research advisory council; members; recommendations A. The psilocybin research advisory council is established in the department consisting of the director or the director's designee who is employed by the department and the following members appointed by the director: 1. One member who has a federal license to study psychedelics and who is a physician licensed pursuant to title 32, chapter 13 or 17. 2. One member who is a military veteran. 3. One member who is a law enforcement officer in this state. 4. One member who is a professor or researcher from a university under the jurisdiction of the Arizona board of regents and who specializes in clinical research or psychedelic studies. B. The director shall serve as chairperson of the advisory council. C. Advisory council members are eligible to receive reimbursement of expenses pursuant to title 38, chapter 4, article 2. D. The advisory council shall: 1. Establish criteria for the clinical trials that qualify to receive research grants. 2. Oversee the application process and review applications for the clinical trial research grants to assist the director in selecting the most credible clinical trials to award the research grants. 3. ensure that all advisory council meetings are open to the public and allow for public testimony. 4. On or before July 1 of each year, make recommendations to the governor, the speaker of the house of representatives, the president of the senate and the department on psychedelic-assisted therapy based on current federal and state research policy. END_STATUTE Sec. 2. Repeal Title 36, chapter 2, article 5, Arizona Revised Statutes, as added by this act, is repealed from and after December 31, 2028. Sec. 3. Appropriation; department of health services; psilocybin research grants; exemption A. The sum of $30,000,000 is appropriated from the state general fund in fiscal year 2023-2024 to the department of health services for psilocybin research grants pursuant to title 36, chapter 2, article 5, Arizona Revised Statutes, as added by this act. B. The appropriation made in subsection A of this section is exempt from the provisions of section 35-190, Arizona Revised Statutes, relating to lapsing of appropriations, except that any monies remaining unexpended and unencumbered on July 1, 2029 revert to the state general fund.
79	79
80	80	Be it enacted by the Legislature of the State of Arizona:
81	81
82	82	Section 1. Title 36, chapter 2, Arizona Revised Statutes, is amended by adding article 5, to read:
83	83
84	84	ARTICLE 5. PSILOCYBIN RESEARCH
85	85
86	86	START_STATUTE36-281. Definitions
87	87
88	88	In this article, unless the context otherwise requires:
89	89
90	90	1. "Advisory council" means the psilocybin research advisory council established by section 36-283.
91	91
92	92	2. "Department" means the department of HEALTH services.
93	93
94	94	3. "Director" means the director of the department of health services. END_STATUTE
95	95
96	96	START_STATUTE36-282. Research grants; psilocybin research; priority; immunity
97	97
98	98	A. The director shall provide from monies appropriated competitive research grants for whole mushroom psilocybin phase one, phase two and phase three clinical trials that are capable of being approved by the United States food and drug administration to evaluate the effects of whole mushroom psilocybin on treating any of the following:
99	99
100	100	1. Post-traumatic stress disorder.
101	101
102	102	2. Symptoms associated with long COVID-19.
103	103
104	104	3. Depression.
105	105
106	106	4. Anxiety disorders.
107	107
108	108	5. Symptoms associated with end-of-life distress.
109	109
110	110	6. Obsessive compulsive disorder.
111	111
112	112	7. substance abuse and addiction disorders.
113	113
114	114	8. Eating disorders.
115	115
116	116	9. Chronic pain.
117	117
118	118	10. Inflammatory disorders.
119	119
120	120	11. Autoimmune disorders.
121	121
122	122	12. Seizure disorders.
123	123
124	124	13. Other degenerative disorders.
125	125
126	126	B. The department shall announce the opening of the application process at least thirty days before applications are available and allow at least ninety days for applicants to complete their submission. The research grants shall be awarded not later than July 1 of each year for three years. If in any year there is not a proposal that meets the criteria for a research grant to be awarded for a whole mushroom psilocybin clinical trial, the director shall postpone the award to the following year.
127	127
128	128	C. Clinical trials that are funded pursuant this section shall prioritize:
129	129
130	130	1. Using whole mushroom psilocybin cultivated under a schedule I license issued by the United States drug enforcement administration.
131	131
132	132	2. Using veterans, first responders, frontline health care workers and persons from underserved communities as the research subjects.
133	133
134	134	D. Notwithstanding title 13, chapter 34, a person who receives a grant for a whole mushroom psilocybin clinical trial pursuant to this section and any of the person's employees working on the clinical trial may not be charged with or prosecuted for possession of psilocybin when the person is working on the clinical trial.END_STATUTE
135	135
136	136	START_STATUTE36-283. Psilocybin research advisory council; members; recommendations
137	137
138	138	A. The psilocybin research advisory council is established in the department consisting of the director or the director's designee who is employed by the department and the following members appointed by the director:
139	139
140	140	1. One member who has a federal license to study psychedelics and who is a physician licensed pursuant to title 32, chapter 13 or 17.
141	141
142	142	2. One member who is a military veteran.
143	143
144	144	3. One member who is a law enforcement officer in this state.
145	145
146	146	4. One member who is a professor or researcher from a university under the jurisdiction of the Arizona board of regents and who specializes in clinical research or psychedelic studies.
147	147
148	148	B. The director shall serve as chairperson of the advisory council.
149	149
150	150	C. Advisory council members are eligible to receive reimbursement of expenses pursuant to title 38, chapter 4, article 2.
151	151
152	152	D. The advisory council shall:
153	153
154	154	1. Establish criteria for the clinical trials that qualify to receive research grants.
155	155
156	156	2. Oversee the application process and review applications for the clinical trial research grants to assist the director in selecting the most credible clinical trials to award the research grants.
157	157
158	158	3. ensure that all advisory council meetings are open to the public and allow for public testimony.
159	159
160	160	4. On or before July 1 of each year, make recommendations to the governor, the speaker of the house of representatives, the president of the senate and the department on psychedelic-assisted therapy based on current federal and state research policy. END_STATUTE
161	161
162	162	Sec. 2. Repeal
163	163
164	164	Title 36, chapter 2, article 5, Arizona Revised Statutes, as added by this act, is repealed from and after December 31, 2028.
165	165
166	166	Sec. 3. Appropriation; department of health services; psilocybin research grants; exemption
167	167
168	168	A. The sum of $30,000,000 is appropriated from the state general fund in fiscal year 2023-2024 to the department of health services for psilocybin research grants pursuant to title 36, chapter 2, article 5, Arizona Revised Statutes, as added by this act.
169	169
170	170	B. The appropriation made in subsection A of this section is exempt from the provisions of section 35-190, Arizona Revised Statutes, relating to lapsing of appropriations, except that any monies remaining unexpended and unencumbered on July 1, 2029 revert to the state general fund.